Education
About Us
Working with TipRanks
Follow Us
Black Diamond Therapeutics, Inc. (BDTX)
:BDTX
Total Valuation
Black Diamond Therapeutics has a market cap or net worth of $146.71M. The enterprise value is ―.
Market Cap$146.71M
Enterprise Value―
Share Statistics
Black Diamond Therapeutics has 56,862,637 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding56,862,637
Owned by Insiders19.47%
Owned by Institutions0.24%
Financial Efficiency
Black Diamond Therapeutics’s return on equity (ROE) is -0.84 and return on invested capital (ROIC) is -77.19%.
Return on Equity (ROE)-0.84
Return on Assets (ROA)-0.57
Return on Invested Capital (ROIC)-77.19%
Return on Capital Employed (ROCE)-0.77
Revenue Per Employee0.00
Profits Per Employee-2.90M
Employee Count24
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Black Diamond Therapeutics is -1.69. Black Diamond Therapeutics’s PEG ratio is -0.18.
PE Ratio-1.69
PS Ratio0.00
PB Ratio1.09
Price to Fair Value1.41
Price to FCF-1.92
Price to Operating Cash Flow-1.46
PEG Ratio-0.18
Income Statement
In the last 12 months, Black Diamond Therapeutics had revenue of 0.00 and earned -69.68M in profits. Earnings per share was -1.27.
Revenue0.00
Gross Profit0.00
Operating Income-78.78M
Pretax Income-69.68M
Net Income-69.68M
EBITDA-78.78M
Earnings Per Share (EPS)-1.27
Cash Flow
In the last 12 months, operating cash flow was -62.30M and capital expenditures 14.73M, giving a free cash flow of -47.58M billion.
Operating Cash Flow-62.30M
Free Cash Flow-47.58M
Free Cash Flow per Share-0.84
Dividends & Yields
Black Diamond Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.99
52-Week Price Change-49.51%
50-Day Moving Average1.77
200-Day Moving Average2.76
Relative Strength Index (RSI)72.22
Average Volume (3m)1.16M
Important Dates
Black Diamond Therapeutics upcoming earnings date is Aug 12, 2025, TBA Not Confirmed.
Last Earnings DateMay 12, 2025
Next Earnings DateAug 12, 2025
Ex-Dividend Date―
Financial Position
Black Diamond Therapeutics as a current ratio of 4.92, with Debt / Equity ratio of 26.64%
Current Ratio4.92
Quick Ratio4.92
Debt to Market Cap0.16
Net Debt to EBITDA0.22
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Black Diamond Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Black Diamond Therapeutics EV to EBITDA ratio is -1.27, with an EV/FCF ratio of -1.61.
EV to Sales0.00
EV to EBITDA-1.27
EV to Free Cash Flow-1.61
EV to Operating Cash Flow-1.61
Balance Sheet
Black Diamond Therapeutics has $98.58M in cash and marketable securities with $22.19M in debt, giving a net cash position of -$76.39M billion.
Cash & Marketable Securities$98.58M
Total Debt$22.19M
Net Cash-$76.39M
Net Cash Per Share-$1.34
Tangible Book Value Per Share$1.51
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Black Diamond Therapeutics is $13.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$13.50
Price Target Upside423.26% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast―
EPS Growth Forecast33.97%